530 related articles for article (PubMed ID: 32249838)
1. Peripheral T cell lymphomas: from the bench to the clinic.
Fiore D; Cappelli LV; Broccoli A; Zinzani PL; Chan WC; Inghirami G
Nat Rev Cancer; 2020 Jun; 20(6):323-342. PubMed ID: 32249838
[TBL] [Abstract][Full Text] [Related]
2. Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.
Carras S; Chartoire D; Mareschal S; Heiblig M; Marçais A; Robinot R; Urb M; Pommier RM; Julia E; Chebel A; Verney A; Bertheau C; Bardel E; Fezelot C; Courtois L; Lours C; Bouska A; Sharma S; Lefebvre C; Rouault JP; Sibon D; Ferrari A; Iqbal J; de Leval L; Gaulard P; Traverse-Glehen A; Sujobert P; Blery M; Salles G; Walzer T; Bachy E; Genestier L
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34043588
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas.
Boulland ML; Kanavaros P; Wechsler J; Casiraghi O; Gaulard P
J Pathol; 1997 Dec; 183(4):432-9. PubMed ID: 9496260
[TBL] [Abstract][Full Text] [Related]
4. CD1d-restricted peripheral T cell lymphoma in mice and humans.
Bachy E; Urb M; Chandra S; Robinot R; Bricard G; de Bernard S; Traverse-Glehen A; Gazzo S; Blond O; Khurana A; Baseggio L; Heavican T; Ffrench M; Crispatzu G; Mondière P; Schrader A; Taillardet M; Thaunat O; Martin N; Dalle S; Le Garff-Tavernier M; Salles G; Lachuer J; Hermine O; Asnafi V; Roussel M; Lamy T; Herling M; Iqbal J; Buffat L; Marche PN; Gaulard P; Kronenberg M; Defrance T; Genestier L
J Exp Med; 2016 May; 213(5):841-57. PubMed ID: 27069116
[TBL] [Abstract][Full Text] [Related]
5. Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
Sandell RF; Boddicker RL; Feldman AL
Curr Oncol Rep; 2017 Apr; 19(4):28. PubMed ID: 28303495
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.
Casulo C; O'Connor O; Shustov A; Fanale M; Friedberg JW; Leonard JP; Kahl BS; Little RF; Pinter-Brown L; Advani R; Horwitz S
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 28040682
[TBL] [Abstract][Full Text] [Related]
7. The microenvironment in T-cell lymphomas: emerging themes.
Gaulard P; de Leval L
Semin Cancer Biol; 2014 Feb; 24():49-60. PubMed ID: 24316493
[TBL] [Abstract][Full Text] [Related]
8. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
9. Challenges and implications of genomics for T-cell lymphomas.
Jacobsen ED; Weinstock DM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):63-68. PubMed ID: 30504292
[TBL] [Abstract][Full Text] [Related]
10. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas.
Foster C; Kuruvilla J
F1000Res; 2020; 9():. PubMed ID: 32934797
[TBL] [Abstract][Full Text] [Related]
11. Molecular underpinning of extranodal NK/T-cell lymphoma.
Huang Y; de Leval L; Gaulard P
Best Pract Res Clin Haematol; 2013 Mar; 26(1):57-74. PubMed ID: 23768641
[TBL] [Abstract][Full Text] [Related]
12. New biomarkers in T-cell lymphomas.
Bisig B; Gaulard P; de Leval L
Best Pract Res Clin Haematol; 2012 Mar; 25(1):13-28. PubMed ID: 22409820
[TBL] [Abstract][Full Text] [Related]
13. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies for peripheral T-cell lymphomas.
Foss FM
Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.
Boddicker RL; Razidlo GL; Feldman AL
Small GTPases; 2019 Jan; 10(1):33-39. PubMed ID: 27898263
[TBL] [Abstract][Full Text] [Related]
16. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
Pinz K; Liu H; Golightly M; Jares A; Lan F; Zieve GW; Hagag N; Schuster M; Firor AE; Jiang X; Ma Y
Leukemia; 2016 Mar; 30(3):701-7. PubMed ID: 26526988
[TBL] [Abstract][Full Text] [Related]
17. c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
Zheng Z; Cheng S; Wu W; Wang L; Zhao Y; Shen Y; Janin A; Zhao WL
J Hematol Oncol; 2014 Dec; 7():88. PubMed ID: 25477070
[TBL] [Abstract][Full Text] [Related]
18. Pathology and biology of peripheral T-cell lymphomas.
de Leval L; Gaulard P
Histopathology; 2011 Jan; 58(1):49-68. PubMed ID: 21261683
[TBL] [Abstract][Full Text] [Related]
19. Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2018 Feb; 13(1):37-43. PubMed ID: 29396703
[TBL] [Abstract][Full Text] [Related]
20. New molecular insights into peripheral T cell lymphomas.
Pileri SA; Piccaluga PP
J Clin Invest; 2012 Oct; 122(10):3448-55. PubMed ID: 23023716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
